Twitter

Chordate Medical presents interim report for Q3 2022

Chordate Medical Holding AB (publ) (“Chordate”) (Nasdaq First North Stockholm: CMH) will publish its interim report for Q3 2022 on Friday November 18, 2022, at 08:30 am.

A webcast teleconference with CEO Anders Weilandt will be broadcast live on Friday November 18 at 02:00 pm. The conference will be followed by a Q&A session. The presentation will be held in Swedish. It is possible to follow the conference via computer or mobile devices.

To register for the web conference, please follow this link:

https://attendee.gotowebinar.com/register/1081159006671885835

Places are limited so we recommend registering well in advance to secure a place.

A recording of the web conference will be available on the company’s website www.chordate.com and on Västra Hamnen Corporate Finance YouTube channel after the conference has ended.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter